Equities research analysts predict that BioTelemetry Inc (NASDAQ:BEAT) will report sales of $103.02 million for the current quarter, according to Zacks. Three analysts have made estimates for BioTelemetry’s earnings, with the highest sales estimate coming in at $104.83 million and the lowest estimate coming in at $101.73 million. BioTelemetry reported sales of $91.74 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 12.3%. The firm is expected to announce its next earnings report on Thursday, February 28th.

On average, analysts expect that BioTelemetry will report full year sales of $398.90 million for the current year, with estimates ranging from $397.60 million to $400.70 million. For the next financial year, analysts expect that the business will post sales of $439.18 million, with estimates ranging from $437.57 million to $440.60 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover BioTelemetry.

BioTelemetry (NASDAQ:BEAT) last released its quarterly earnings results on Tuesday, October 30th. The medical research company reported $0.53 EPS for the quarter, beating analysts’ consensus estimates of $0.32 by $0.21. The business had revenue of $100.00 million during the quarter, compared to analyst estimates of $97.89 million. BioTelemetry had a return on equity of 22.56% and a net margin of 4.34%. BioTelemetry’s quarterly revenue was up 23.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.16 EPS.

A number of research firms recently commented on BEAT. BidaskClub lowered BioTelemetry from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 18th. Raymond James decreased their target price on BioTelemetry from $66.00 to $64.00 and set an “outperform” rating for the company in a research report on Wednesday, October 31st. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. BioTelemetry presently has an average rating of “Buy” and a consensus price target of $61.17.

In other news, SVP Peter Ferola sold 75,000 shares of the firm’s stock in a transaction on Thursday, November 1st. The stock was sold at an average price of $60.61, for a total transaction of $4,545,750.00. Following the completion of the sale, the senior vice president now directly owns 90,065 shares of the company’s stock, valued at approximately $5,458,839.65. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Robert J. Rubin sold 8,489 shares of the firm’s stock in a transaction on Thursday, November 1st. The shares were sold at an average price of $60.36, for a total value of $512,396.04. Following the sale, the director now directly owns 140,040 shares of the company’s stock, valued at $8,452,814.40. The disclosure for this sale can be found here. Company insiders own 8.30% of the company’s stock.

Several hedge funds have recently bought and sold shares of BEAT. Schwab Charles Investment Management Inc. raised its stake in shares of BioTelemetry by 10.2% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 163,248 shares of the medical research company’s stock valued at $7,347,000 after acquiring an additional 15,139 shares during the period. BlackRock Inc. increased its stake in BioTelemetry by 8.0% during the 2nd quarter. BlackRock Inc. now owns 4,597,288 shares of the medical research company’s stock worth $206,877,000 after buying an additional 339,306 shares during the period. Legal & General Group Plc increased its stake in BioTelemetry by 7.4% during the 2nd quarter. Legal & General Group Plc now owns 61,986 shares of the medical research company’s stock worth $2,796,000 after buying an additional 4,245 shares during the period. OppenheimerFunds Inc. purchased a new stake in BioTelemetry during the 2nd quarter worth $205,000. Finally, Raymond James & Associates increased its stake in BioTelemetry by 11.7% during the 2nd quarter. Raymond James & Associates now owns 85,338 shares of the medical research company’s stock worth $3,840,000 after buying an additional 8,971 shares during the period. Institutional investors own 88.90% of the company’s stock.

NASDAQ BEAT opened at $66.73 on Friday. The firm has a market capitalization of $2.20 billion, a P/E ratio of 68.79, a P/E/G ratio of 3.71 and a beta of 1.75. BioTelemetry has a 12 month low of $29.85 and a 12 month high of $74.73. The company has a quick ratio of 2.50, a current ratio of 2.68 and a debt-to-equity ratio of 0.66.

About BioTelemetry

BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.

Read More: How do taxes affect a CDs total return?

Get a free copy of the Zacks research report on BioTelemetry (BEAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.